<DOC>
	<DOC>NCT02279862</DOC>
	<brief_summary>The purpose of this study is to examine the safety and effectiveness (how well the drug works) of two different doses (3 mg/kg and 10 mg/kg) of Ipilimumab (Yervoyâ„¢) in patients with metastatic castration resistant prostate cancer.</brief_summary>
	<brief_title>Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive</brief_title>
	<detailed_description>Prostate Cancer Clinical Trials Working Group 2 (PCWG2) Response Evaluation Criteria In Solid Tumors (RECIST)</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Prostate cancer with metastases Prostate cancer should be castration resistant Progression during hormonal therapy Visceral metastases (eg liver, lung or brain metastases) Prior treatment with any immunotherapy for prostate cancer Prior or ongoing cytotoxic therapy for prostate cancer Autoimmune disease Inadequate hematologic, renal, or hepatic function</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>